F-Phenibut FAA – Powder
From €39.80
F-Phenibut FAA (Fluorophenibut Free Amino Acid) is a modified version of Phenibut, known for its potential to reduce anxiety, enhance mood, and promote relaxation. As the free amino acid (FAA) form, it provides a purer version of the compound, which may offer longer-lasting effects compared to other forms like the HCl salt.
For a more detailed description and lab analysis, please see the sections below.
In stock
Worldwide Delivery: We ship to most international destinations with tracked services.
F-Phenibut FAA – Powder
Introduction:
F-Phenibut FAA (more formally 4-fluorophenibut or β-(4-fluorophenyl)-GABA) is a synthetic chemical compound belonging to a family of substances called GABAergic compounds — a term worth unpacking, because it’s the key to everything that follows.
Let’s break that intimidating word down with an analogy.
The Brake Pedal of the Nervous System: A Quick Analogy
Imagine the nervous system as a car that is always running. Sometimes the engine revs too high — that’s what anxiety, racing thoughts, or an overactive stress response feels like. The nervous system has a built-in brake pedal for this engine, and its main “brake fluid” is a chemical messenger (a neurotransmitter) called GABA (gamma-aminobutyric acid).
- Glutamate is the gas pedal (excitatory — it makes neurons fire).
- GABA is the brake pedal (inhibitory — it calms neurons down).
When GABA works properly, the system stays balanced and calm.
Now here’s an important refinement to the analogy: the brain’s GABA system has more than one type of brake pedal. The two best-studied are called GABAₐ and GABAB receptors — think of them as a fast-acting foot brake (GABAₐ) and a slower, longer-lasting parking brake (GABAB). Different substances press on different pedals.
- Benzodiazepines (like diazepam/Valium) and alcohol largely press the GABAₐ “foot brake” — and they do so by enhancing GABA that’s already there.
- Baclofen and F-Phenibut press the GABAB “parking brake” — and unlike benzodiazepines, they directly activate that receptor themselves, mimicking GABA rather than merely boosting it.
This distinction matters, and we’ll return to it.
Where Does F-Phenibut Come From?
F-Phenibut is a fluorinated analogue — a close chemical relative — of a family of compounds built from the GABA backbone. To understand it, we need to meet its relatives.
A Small Chemical Family, One Atom at a Time
Think of these compounds as the same basic skeleton with a single “decoration” attached to a ring:
| Compound | The “Decoration” on the Phenyl Ring | Notes |
|---|---|---|
| GABA itself | none (no ring at all) | The natural neurotransmitter; does not cross into the brain well |
| Phenibut | a plain phenyl ring (just hydrogen) | Developed in Russia in the 1960s; a prescription anxiolytic there |
| Baclofen | a chlorine atom on that ring | A widely prescribed muscle relaxant |
| F-Phenibut | a fluorine atom instead of chlorine | The subject of this article |
Notice the pattern: F-Phenibut FAA is essentially baclofen with the chlorine atom swapped for a fluorine atom — or, equivalently, phenibut with a fluorine added to the ring. Chemists call this replacing a substituent at the “para position.”
The Crucial Insight: Small structural changes can produce big functional differences. Because fluorine is small but highly electronegative (it pulls electrons toward itself strongly), swapping chlorine for fluorine changes how the whole molecule distributes its charge, how tightly it binds to its target receptors, and how quickly the body metabolizes it.
Phenibut: The Historical Parent
Phenibut was first synthesized in the early 1960s in what was then the USSR, by the team of V. V. Perekalin at the Herzen Pedagogical Institute in Leningrad. It entered clinical use as an anti-anxiety and “nootropic” (cognition-enhancing) agent, and was even included in Soviet cosmonaut medical kits. Its key design cleverness: adding a phenyl ring (a hexagonal ring of six carbon atoms) to the GABA molecule acted like a “passport,” letting the compound cross the blood–brain barrier far more easily than plain GABA can. F-Phenibut follows this same design principle, with the fluorine modification layered on top.
“F-PHENIBUT FAA ” ?
When you see “F-Phenibut FAA,” the “FAA” stands for Free Amino Acid.
Many compounds can exist in different chemical “forms” — a bit like the same substance presented as granules, cubes, or syrup. Phenibut and its relatives are commonly distributed in two main salt forms plus the free form:
| Form | What It Is | Notable Traits |
|---|---|---|
| FAA (Free Amino Acid) | The pure, uncharged molecule (“free base”) | No acid attached; closer to neutral pH; slower to dissolve in water; non-crystalline |
| HCl (hydrochloride salt) | The molecule bound to hydrochloric acid | Acidic; dissolves readily in water; sour or bitter taste; crystalline |
Think of a salt as the molecule wearing a “coat” of another compound (an acid) to make it more stable, crystalline, and water-soluble. The FAA form has no such coat — it’s the bare molecule.
Two practical points worth being precise about:
- Mass matters. Because the HCl salt carries the extra weight of the hydrochloric acid, a gram of the salt contains less of the active molecule than a gram of the FAA form (for phenibut, roughly 83% vs. 100% by mass). This is an arithmetic difference in how much powder you weigh — not a difference in what the molecule does once dissolved.
How It Works at the Molecular Level
The mechanism of F-Phenibut FAA is best described with careful precision, because a common over-simplification gets it wrong.
Primary Action: A GABAB Receptor Agonist
The best-supported evidence indicates that F-Phenibut acts primarily as an agonist (activator) at the GABAB receptor — and it does so selectively, meaning it strongly prefers GABAB over GABAₐ. In one classic binding study, its potency at GABAB (IC₅₀ ≈ 1.7 μM) was roughly 60-fold greater than at GABAₐ (> 100 μM).
This makes F-Phenibut FAA pharmacologically much closer to baclofen than to phenibut (or to benzodiazepines/alcohol). Let’s be precise about what “agonist” means here:
- An agonist directly activates a receptor, pretending to be the natural chemical (GABA).
- A positive modulator (like a benzodiazepine) simply turns up the volume on GABA that’s already present, without activating the receptor on its own.
F-Phenibut is in the first camp. It binds to the GABAB receptor and switches it on, mimicking GABA itself.
A 2020 laboratory study on mouse brain cells demonstrated this directly: F-Phenibut activated GABAB receptors on cerebellar neurons, opening potassium channels (an “outward current”) that made the cells less electrically excitable — essentially quieting their firing. That’s the brake pedal at work, at the level of individual cells.
Secondary Action: Voltage-Gated Calcium Channels (An Important Caveat)
Phenibut is also known to bind to a protein called the α2δ subunit of voltage-gated calcium channels — the same target used by drugs like gabapentin and pregabalin. Slowing calcium entry into overactive neurons further dampens excitability (another way of taking a foot off the “gas pedal”).
This has led many sources to assume F-Phenibut shares this second mechanism. But here’s the honest state of the evidence:
Direct binding data for F-Phenibut at the α2δ calcium channel subunit are sparse or absent. The inference is based on its structural relatives, not on measurements of F-Phenibut itself. Notably, baclofen — its closest relative — is actually a weak binder at α2δ (much weaker than phenibut or gabapentin).
So the two-mechanism picture (GABAB + calcium channel) is plausible but unconfirmed for F-Phenibut specifically. Responsible framing treats the GABAB agonism as established and the calcium-channel activity as a hypothesis.
The “Double Brake” Analogy, Revised:
- Established: F-Phenibut presses the GABAB “parking brake” by directly switching it on.
- Unconfirmed: Whether it also takes a foot off the “gas pedal” via calcium-channel blockade, as phenibut does.
Reported Effects & Potency: Separating Data from Claims
Reported Effects and Observed Properties
Because F-Phenibut was never marketed and has almost no clinical literature, descriptions of its effects come primarily from user reports and a small number of laboratory studies. With that caveat firmly in mind, it is described as producing:
- Anxiolysis — reduced anxiety (the most consistent reported effect).
- Sedation and sleep facilitation — consistent with its GABAB agonism.
- Muscle relaxation — again typical of GABAB activation (baclofen is a muscle relaxant for this reason).
- Mood elevation and mild euphoria at higher concentrations.
- Reduced social inhibition — an effect commonly compared, loosely, to a “clear-headed” version of alcohol’s loosening.
A recurring theme in reports is that F-Phenibut feels “cleaner” and less sedating than regular phenibut, arriving faster and leaving sooner. But treat these timing figures — commonly quoted as onset in roughly 20–45 minutes and duration of perhaps 4–8 hours — as anecdotal, not clinically validated. No rigorous pharmacokinetic study in humans establishes these numbers.
On Potency: A Caution About Widely Repeated Figures
One of the most frequently repeated claims about F-Phenibut is that it is “5–10 times more potent than phenibut.” Here is what the evidence actually supports:
- The peer-reviewed literature does establish a potency ranking as a GABAB agonist: baclofen > F-Phenibut > phenibut. F-Phenibut sits between the two.
- The specific “5–10×” multiplier, however, traces back to unpublished, vendor-associated laboratory results posted on internet forums — not to peer-reviewed studies. It has been repeated so widely that it is often mistaken for established fact.
The genuinely established points are more modest and more defensible: F-Phenibut is a more potent GABAB agonist than phenibut and less potent than baclofen, with a fluorine-for-chlorine difference from baclofen. Exact ratios beyond that are unverified. This is a good example of how an unverified number can harden into “common knowledge” through repetition.
The Risks: What the Evidence Actually Says
Scientific communication demands honesty about risk. The most reliable risk information comes from its two closest relatives — phenibut and baclofen — both of which are well-characterized. The class properties are concerning enough to warrant real caution.
1. Tolerance and Dependence Develop Rapidly
The nervous system is extraordinarily adaptive. When the GABAB brake is repeatedly pressed from outside, the system responds by turning down its own natural brake sensitivity — like partially closing a valve. This is tolerance: more of the compound is needed to get the same effect. With phenibut, tolerance can develop within days to a couple of weeks of regular use — early Soviet studies noted that doses often needed to be increased 25–33% after just two weeks. Dependence, where the system can no longer maintain a normal baseline without the compound, follows from sustained use.
2. Withdrawal Can Be Severe
Because these compounds press the brake hard, abruptly removing them releases the brake — a “rebound.” Phenibut withdrawal is well documented in the clinical literature and can be severe, including:
- Rebound anxiety, agitation, and insomnia
- Tremor, racing heart, sweating
- Nausea and vomiting
- In serious cases, psychosis, delirium, hallucinations, and seizures
Withdrawal is among the most dangerous aspects of this drug class and is a primary reason phenibut-type compounds warrant respect. The evidence comes from phenibut specifically; F-Phenibut, sharing a closely related mechanism, carries the same class concerns while lacking the same documentation.
3. Dangerous Interactions
Combining GABAB agonists with other central-nervous-system depressants — alcohol, opioids, benzodiazepines, sleep medications — multiplies the braking effect. This can produce dangerous over-sedation and suppressed breathing. The interaction risk is a class property of sedatives and is well established.
A Balanced Bottom Line
| Dimension | Summary |
|---|---|
| What it is | A synthetic GABA analogue, essentially baclofen with chlorine swapped for fluorine (or phenibut with a fluorine added to the ring). |
| “FAA” meaning | Free Amino Acid — the uncharged, non-salt form of the molecule; a physical/chemical form, not a statement of purity. |
| Primary mechanism (established) | A selective GABAB receptor agonist, directly switching on the nervous system’s “parking brake.” |
| Secondary mechanism (unconfirmed) | Possible activity at α2δ calcium-channel subunits, inferred from phenibut but not directly measured for F-Phenibut. |
| Potency | More potent than phenibut, less potent than baclofen — as a GABAB agonist. The widely repeated “5–10× phenibut” figure is unverified, from non-peer-reviewed sources. |
| Reported effects | Anxiety reduction, sedation, muscle relaxation, mood lift — primarily anecdotal. |
| Primary risks | Rapid tolerance, potentially severe withdrawal (documented extensively for phenibut), dangerous interactions with other depressants, unregulated purity, easy mis-measurement. |
| Responsible framing | An under-studied compound whose closest relatives carry well-documented risks. |
The honest scientific summary is this: F-Phenibut FAA is a potent, fast-acting GABAB receptor agonist with an established mechanism of action — and a risk profile, inherited from its close chemical relatives, that is not remotely trivial. The very property that gives it its characteristic activity (strong, reliable braking of an overactive nervous system) is the same property that makes tolerance and withdrawal dangerous when the brake is removed.
For the curious reader, the key takeaway is a deeper one about chemistry itself: a single atom — a fluorine in place of a chlorine — takes a known compound (baclofen) and yields a related molecule with meaningfully different potency and kinetics.
This content is for educational and informational purposes only. It is not medical advice. F-Phenibut is not approved by the FDA for any medical use in the United States and is a controlled or prohibited substance in several countries; regulatory status varies by jurisdiction.
Lab analysis — Certificates of Analysis
Every batch is independently tested by HPLC/LC-MS. Purity for current lots: ≥98%. Select a lot to view the full report.
Chemical Informations
CAS Number:1858241-03-8
Purity:≥98%
Melting Point:Unknown
Molecular Formula:C10FH12NO2 •HClSynonyms:4-Amino-3-(4-fluorophenyl)butanoic acid hydrochloride, 4-Amino-3-(4-fluorophenyl)butyric acid, 4-Fluorophenibut hydrochloride, β-(4-fluorophenyl)-γ-aminobutyric acid hydrochloride, CGP-11130, Fluorophenibut HCL, F-Phenibut, Fluoribut, FenibutPubChem CID:103611SMILES:C1(F)=CC=C(C=C1)C(CC(=O)O)CN
Technical Information
Store at room temperature or cooler, in a sealed airtight container, protected from heat, light and humidity.
| Application: | F-Phenibut HCl (4-Fluorophenibut hydrochloride) is a several-fold more potent derivative of the nootropic and anxiolytic gamma amino butyric acid derivative, Phenibut; useful as a GABA<sub>B and α2δ subunit-containing voltage-gated calcium channel ligand | ||
|---|---|---|---|
| Appearance: | White or off-white crystalline powder | ||
| Physical State: | Solid | Solub | Freely soluble in Ethanol, Water. |
| Storage: | |||
| Stability: | Stable for at least two years when stored as above. |
F-Phenibut FAA – Powder
Introduction:
F-Phenibut FAA (more formally 4-fluorophenibut or β-(4-fluorophenyl)-GABA) is a synthetic chemical compound belonging to a family of substances called GABAergic compounds — a term worth unpacking, because it’s the key to everything that follows.
Let’s break that intimidating word down with an analogy.
The Brake Pedal of the Nervous System: A Quick Analogy
Imagine the nervous system as a car that is always running. Sometimes the engine revs too high — that’s what anxiety, racing thoughts, or an overactive stress response feels like. The nervous system has a built-in brake pedal for this engine, and its main “brake fluid” is a chemical messenger (a neurotransmitter) called GABA (gamma-aminobutyric acid).
- Glutamate is the gas pedal (excitatory — it makes neurons fire).
- GABA is the brake pedal (inhibitory — it calms neurons down).
When GABA works properly, the system stays balanced and calm.
Now here’s an important refinement to the analogy: the brain’s GABA system has more than one type of brake pedal. The two best-studied are called GABAₐ and GABAB receptors — think of them as a fast-acting foot brake (GABAₐ) and a slower, longer-lasting parking brake (GABAB). Different substances press on different pedals.
- Benzodiazepines (like diazepam/Valium) and alcohol largely press the GABAₐ “foot brake” — and they do so by enhancing GABA that’s already there.
- Baclofen and F-Phenibut press the GABAB “parking brake” — and unlike benzodiazepines, they directly activate that receptor themselves, mimicking GABA rather than merely boosting it.
This distinction matters, and we’ll return to it.
Where Does F-Phenibut Come From?
F-Phenibut is a fluorinated analogue — a close chemical relative — of a family of compounds built from the GABA backbone. To understand it, we need to meet its relatives.
A Small Chemical Family, One Atom at a Time
Think of these compounds as the same basic skeleton with a single “decoration” attached to a ring:
| Compound | The “Decoration” on the Phenyl Ring | Notes |
|---|---|---|
| GABA itself | none (no ring at all) | The natural neurotransmitter; does not cross into the brain well |
| Phenibut | a plain phenyl ring (just hydrogen) | Developed in Russia in the 1960s; a prescription anxiolytic there |
| Baclofen | a chlorine atom on that ring | A widely prescribed muscle relaxant |
| F-Phenibut | a fluorine atom instead of chlorine | The subject of this article |
Notice the pattern: F-Phenibut FAA is essentially baclofen with the chlorine atom swapped for a fluorine atom — or, equivalently, phenibut with a fluorine added to the ring. Chemists call this replacing a substituent at the “para position.”
The Crucial Insight: Small structural changes can produce big functional differences. Because fluorine is small but highly electronegative (it pulls electrons toward itself strongly), swapping chlorine for fluorine changes how the whole molecule distributes its charge, how tightly it binds to its target receptors, and how quickly the body metabolizes it.
Phenibut: The Historical Parent
Phenibut was first synthesized in the early 1960s in what was then the USSR, by the team of V. V. Perekalin at the Herzen Pedagogical Institute in Leningrad. It entered clinical use as an anti-anxiety and “nootropic” (cognition-enhancing) agent, and was even included in Soviet cosmonaut medical kits. Its key design cleverness: adding a phenyl ring (a hexagonal ring of six carbon atoms) to the GABA molecule acted like a “passport,” letting the compound cross the blood–brain barrier far more easily than plain GABA can. F-Phenibut follows this same design principle, with the fluorine modification layered on top.
“F-PHENIBUT FAA ” ?
When you see “F-Phenibut FAA,” the “FAA” stands for Free Amino Acid.
Many compounds can exist in different chemical “forms” — a bit like the same substance presented as granules, cubes, or syrup. Phenibut and its relatives are commonly distributed in two main salt forms plus the free form:
| Form | What It Is | Notable Traits |
|---|---|---|
| FAA (Free Amino Acid) | The pure, uncharged molecule (“free base”) | No acid attached; closer to neutral pH; slower to dissolve in water; non-crystalline |
| HCl (hydrochloride salt) | The molecule bound to hydrochloric acid | Acidic; dissolves readily in water; sour or bitter taste; crystalline |
Think of a salt as the molecule wearing a “coat” of another compound (an acid) to make it more stable, crystalline, and water-soluble. The FAA form has no such coat — it’s the bare molecule.
Two practical points worth being precise about:
- Mass matters. Because the HCl salt carries the extra weight of the hydrochloric acid, a gram of the salt contains less of the active molecule than a gram of the FAA form (for phenibut, roughly 83% vs. 100% by mass). This is an arithmetic difference in how much powder you weigh — not a difference in what the molecule does once dissolved.
How It Works at the Molecular Level
The mechanism of F-Phenibut FAA is best described with careful precision, because a common over-simplification gets it wrong.
Primary Action: A GABAB Receptor Agonist
The best-supported evidence indicates that F-Phenibut acts primarily as an agonist (activator) at the GABAB receptor — and it does so selectively, meaning it strongly prefers GABAB over GABAₐ. In one classic binding study, its potency at GABAB (IC₅₀ ≈ 1.7 μM) was roughly 60-fold greater than at GABAₐ (> 100 μM).
This makes F-Phenibut FAA pharmacologically much closer to baclofen than to phenibut (or to benzodiazepines/alcohol). Let’s be precise about what “agonist” means here:
- An agonist directly activates a receptor, pretending to be the natural chemical (GABA).
- A positive modulator (like a benzodiazepine) simply turns up the volume on GABA that’s already present, without activating the receptor on its own.
F-Phenibut is in the first camp. It binds to the GABAB receptor and switches it on, mimicking GABA itself.
A 2020 laboratory study on mouse brain cells demonstrated this directly: F-Phenibut activated GABAB receptors on cerebellar neurons, opening potassium channels (an “outward current”) that made the cells less electrically excitable — essentially quieting their firing. That’s the brake pedal at work, at the level of individual cells.
Secondary Action: Voltage-Gated Calcium Channels (An Important Caveat)
Phenibut is also known to bind to a protein called the α2δ subunit of voltage-gated calcium channels — the same target used by drugs like gabapentin and pregabalin. Slowing calcium entry into overactive neurons further dampens excitability (another way of taking a foot off the “gas pedal”).
This has led many sources to assume F-Phenibut shares this second mechanism. But here’s the honest state of the evidence:
Direct binding data for F-Phenibut at the α2δ calcium channel subunit are sparse or absent. The inference is based on its structural relatives, not on measurements of F-Phenibut itself. Notably, baclofen — its closest relative — is actually a weak binder at α2δ (much weaker than phenibut or gabapentin).
So the two-mechanism picture (GABAB + calcium channel) is plausible but unconfirmed for F-Phenibut specifically. Responsible framing treats the GABAB agonism as established and the calcium-channel activity as a hypothesis.
The “Double Brake” Analogy, Revised:
- Established: F-Phenibut presses the GABAB “parking brake” by directly switching it on.
- Unconfirmed: Whether it also takes a foot off the “gas pedal” via calcium-channel blockade, as phenibut does.
Reported Effects & Potency: Separating Data from Claims
Reported Effects and Observed Properties
Because F-Phenibut was never marketed and has almost no clinical literature, descriptions of its effects come primarily from user reports and a small number of laboratory studies. With that caveat firmly in mind, it is described as producing:
- Anxiolysis — reduced anxiety (the most consistent reported effect).
- Sedation and sleep facilitation — consistent with its GABAB agonism.
- Muscle relaxation — again typical of GABAB activation (baclofen is a muscle relaxant for this reason).
- Mood elevation and mild euphoria at higher concentrations.
- Reduced social inhibition — an effect commonly compared, loosely, to a “clear-headed” version of alcohol’s loosening.
A recurring theme in reports is that F-Phenibut feels “cleaner” and less sedating than regular phenibut, arriving faster and leaving sooner. But treat these timing figures — commonly quoted as onset in roughly 20–45 minutes and duration of perhaps 4–8 hours — as anecdotal, not clinically validated. No rigorous pharmacokinetic study in humans establishes these numbers.
On Potency: A Caution About Widely Repeated Figures
One of the most frequently repeated claims about F-Phenibut is that it is “5–10 times more potent than phenibut.” Here is what the evidence actually supports:
- The peer-reviewed literature does establish a potency ranking as a GABAB agonist: baclofen > F-Phenibut > phenibut. F-Phenibut sits between the two.
- The specific “5–10×” multiplier, however, traces back to unpublished, vendor-associated laboratory results posted on internet forums — not to peer-reviewed studies. It has been repeated so widely that it is often mistaken for established fact.
The genuinely established points are more modest and more defensible: F-Phenibut is a more potent GABAB agonist than phenibut and less potent than baclofen, with a fluorine-for-chlorine difference from baclofen. Exact ratios beyond that are unverified. This is a good example of how an unverified number can harden into “common knowledge” through repetition.
The Risks: What the Evidence Actually Says
Scientific communication demands honesty about risk. The most reliable risk information comes from its two closest relatives — phenibut and baclofen — both of which are well-characterized. The class properties are concerning enough to warrant real caution.
1. Tolerance and Dependence Develop Rapidly
The nervous system is extraordinarily adaptive. When the GABAB brake is repeatedly pressed from outside, the system responds by turning down its own natural brake sensitivity — like partially closing a valve. This is tolerance: more of the compound is needed to get the same effect. With phenibut, tolerance can develop within days to a couple of weeks of regular use — early Soviet studies noted that doses often needed to be increased 25–33% after just two weeks. Dependence, where the system can no longer maintain a normal baseline without the compound, follows from sustained use.
2. Withdrawal Can Be Severe
Because these compounds press the brake hard, abruptly removing them releases the brake — a “rebound.” Phenibut withdrawal is well documented in the clinical literature and can be severe, including:
- Rebound anxiety, agitation, and insomnia
- Tremor, racing heart, sweating
- Nausea and vomiting
- In serious cases, psychosis, delirium, hallucinations, and seizures
Withdrawal is among the most dangerous aspects of this drug class and is a primary reason phenibut-type compounds warrant respect. The evidence comes from phenibut specifically; F-Phenibut, sharing a closely related mechanism, carries the same class concerns while lacking the same documentation.
3. Dangerous Interactions
Combining GABAB agonists with other central-nervous-system depressants — alcohol, opioids, benzodiazepines, sleep medications — multiplies the braking effect. This can produce dangerous over-sedation and suppressed breathing. The interaction risk is a class property of sedatives and is well established.
A Balanced Bottom Line
| Dimension | Summary |
|---|---|
| What it is | A synthetic GABA analogue, essentially baclofen with chlorine swapped for fluorine (or phenibut with a fluorine added to the ring). |
| “FAA” meaning | Free Amino Acid — the uncharged, non-salt form of the molecule; a physical/chemical form, not a statement of purity. |
| Primary mechanism (established) | A selective GABAB receptor agonist, directly switching on the nervous system’s “parking brake.” |
| Secondary mechanism (unconfirmed) | Possible activity at α2δ calcium-channel subunits, inferred from phenibut but not directly measured for F-Phenibut. |
| Potency | More potent than phenibut, less potent than baclofen — as a GABAB agonist. The widely repeated “5–10× phenibut” figure is unverified, from non-peer-reviewed sources. |
| Reported effects | Anxiety reduction, sedation, muscle relaxation, mood lift — primarily anecdotal. |
| Primary risks | Rapid tolerance, potentially severe withdrawal (documented extensively for phenibut), dangerous interactions with other depressants, unregulated purity, easy mis-measurement. |
| Responsible framing | An under-studied compound whose closest relatives carry well-documented risks. |
The honest scientific summary is this: F-Phenibut FAA is a potent, fast-acting GABAB receptor agonist with an established mechanism of action — and a risk profile, inherited from its close chemical relatives, that is not remotely trivial. The very property that gives it its characteristic activity (strong, reliable braking of an overactive nervous system) is the same property that makes tolerance and withdrawal dangerous when the brake is removed.
For the curious reader, the key takeaway is a deeper one about chemistry itself: a single atom — a fluorine in place of a chlorine — takes a known compound (baclofen) and yields a related molecule with meaningfully different potency and kinetics.
This content is for educational and informational purposes only. It is not medical advice. F-Phenibut is not approved by the FDA for any medical use in the United States and is a controlled or prohibited substance in several countries; regulatory status varies by jurisdiction.
Lab analysis — Certificates of Analysis
Every batch is independently tested by HPLC/LC-MS. Purity for current lots: ≥98%. Select a lot to view the full report.
Chemical Informations
CAS Number:1858241-03-8
Purity:≥98%
Melting Point:Unknown
Molecular Formula:C10FH12NO2 •HClSynonyms:4-Amino-3-(4-fluorophenyl)butanoic acid hydrochloride, 4-Amino-3-(4-fluorophenyl)butyric acid, 4-Fluorophenibut hydrochloride, β-(4-fluorophenyl)-γ-aminobutyric acid hydrochloride, CGP-11130, Fluorophenibut HCL, F-Phenibut, Fluoribut, FenibutPubChem CID:103611SMILES:C1(F)=CC=C(C=C1)C(CC(=O)O)CN
Technical Information
Store at room temperature or cooler, in a sealed airtight container, protected from heat, light and humidity.
| Application: | F-Phenibut HCl (4-Fluorophenibut hydrochloride) is a several-fold more potent derivative of the nootropic and anxiolytic gamma amino butyric acid derivative, Phenibut; useful as a GABA<sub>B and α2δ subunit-containing voltage-gated calcium channel ligand | ||
|---|---|---|---|
| Appearance: | White or off-white crystalline powder | ||
| Physical State: | Solid | Solub | Freely soluble in Ethanol, Water. |
| Storage: | |||
| Stability: | Stable for at least two years when stored as above. |
